まとめ
エシェリキア・コライアスパラギナゼは腫瘍のグリシンを枯渇させ,リンパサルコマの成長を阻害する. この効果は,グリシンまたはアスパラジンによって逆転し, purin合成と腫瘍進行におけるグリシンの役割を強調します.
科学分野:
- バイオケミストリー バイオケミストリー
- 腫瘍学 腫瘍学
- 薬理学 薬理学とは
背景:
- マウスの6C3HEDリンパサルコマは,Escherichia coliアスパラギナゼに敏感である.
- アスパラギナゼ治療は,腫瘍内の細胞グリシン濃度の低下につながる.
- アスパラギナーゼに耐性のある腫瘍は,このグリシン欠乏を示さない.
研究 の 目的:
- 6C3HEDリンパ肉腫における細胞グリシン濃度に対するEscherichia coliアスパラギナーゼの影響を調査する.
- アスパラギナーゼ誘発腫瘍阻害におけるグリシン減少の役割を決定する.
- アミノ酸投与でアスパラギナゼの効果を逆転させる可能性を調査する.
主な方法:
- 6C3HEDリンパ肉腫を有するC3H/HEマウスにEscherichia coliアスパラギナーゼまたはコウモリ血清を投与する.
- 腫瘍組織における細胞グリシン濃度の測定.
- リンパサルコマの抑制と,腸内アミノ酸注射による効果の逆転の評価.
主要な成果:
- アスパラギナースの投与は,敏感リンパ肉腫におけるグリシン濃度を有意に低下させた.
- アスパラギナゼ耐性腫瘍では,グリシンの有意な減少は観察されなかった.
- アスパラジンまたはグリシンの腸内注射は,リンパサルコマに対するアスパラギナーゼの抑制効果を逆転させた.
- ライシン,スレオニン,セリン,アスパルチン酸を含む他のアミノ酸は,抑制を逆転させなかった.
結論:
- 細胞グリシンの枯渇は,アスパラギナーゼが6C3HEDリンパサルコマの成長を抑制する重要なメカニズムです.
- ピューリン合成におけるグリシンの役割は,腫瘍細胞の生存能力にとって重要であり,その枯渇が治療効果の重要な要因になる可能性があります.
- アスパラギンとグリシンによる特定の逆転は,標的の代謝経路がアスパラギナーゼの作用に関与することを示唆しています.
関連する概念動画
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...